Interferon in relapsing-remitting multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2001-10-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD002002PMID 11687131PMCID PMC7017973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of the FIM™ Instrument in a Trial of Intramuscular Interferon &bgr;-1a for Disease Progression in Relapsing-Remitting Multiple Sclerosis

  2003cited by this paper
• Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

  2003cited by this paper
• Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

  2000cited by this paper
• Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment?

  2000cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• A longitudinal study of brain atrophy in relapsing multiple sclerosis

  1999cited by this paper
• Progress in determining the causes and treatment of multiple sclerosis

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis

  1999cited by this paper
• Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading

  1999cited by this paper
• Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

  1999cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.

  1999cited by this paper
• Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis

  1999cited by this paper
• Interferon β treatment for multiple sclerosis

  1999cited by this paper
• Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

  1999cited by this paper
• Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon β1a

  1999cited by this paper
• The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

  1999cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Anticytokine antibodies in beta‐interferon‐treated patients

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

  1998cited by this paper
• Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

  1998cited by this paper
• Anticytokine antibodies in beta‐interferon‐treated patients

  1998cited by this paper
• Anticytokine antibodies in beta‐interferon‐treated patients

  1998cited by this paper
• Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis

  1998cited by this paper
• Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

  1997cited by this paper
• Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

  1997cited by this paper
• Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.

  1997cited by this paper
• Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

  1997cited by this paper
• The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.

  1997cited by this paper
• Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist

  1997cited by this paper
• Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

  1997cited by this paper
• Treatment of multiple sclerosis with interferon beta-1b

  1997cited by this paper
• Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.

  1996cited by this paper
• Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

  1996cited by this paper
• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

  1996cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Does interferon beta cause initial exacerbation of multiple sclerosis?

  1995cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

  1995cited by this paper
• Intracranial hypotension

  1994cited by this paper
• Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis

  1994cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up

  1993cited by this paper
• Interferon beta in multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS)

  1992cited by this paper
• Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

  1990cited by this paper
• Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.

  1989cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

  1989cited by this paper
• Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.

  1986cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• The Effects of Long-Term Administration of Recombinant Alpha-2 Interferon on Lymphocyte Subsets, Proliferation, and Suppressor Cell Function in Multiple Sclerosis

  1986cited by this paper
• Systemic Recombinant α-2Interferon Therapy in Relapsing Multiple Sclerosis

  1986cited by this paper
• Beta blockade during and after myocardial infarction: an overview of the randomized trials.

  1985cited by this paper
• Systemic alpha‐interferon therapy of multiple sclerosis

  1984cited by this paper
• Clinical Trial of Natural Alpha Interferon in Multiple Sclerosis a

  1984cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

  1983cited by this paper
• Intrathecal interferon reduces exacerbations of multiple sclerosis.

  1981cited by this paper
• PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

  1965cited by this paper
• On the evaluation of disability in multiple sclerosis

  1961cited by this paper

• Quality of the systematic reviews in cochrane multiple sclerosis related articles

  2024cites this paper
• Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis.

  2024cites this paper
• The molecular dynamics simulation of coronavirus- based compound (6OHW structure) interaction with interferon beta-1a protein at different temperatures and pressures: Virus destruction process

  2024cites this paper
• Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.

  2024cites this paper
• The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

  2022cites this paper
• Multiple sclerosis in Peru: National prevalence study using capture-recapture analysis.

  2021cites this paper
• Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery

  2021cites this paper
• Alternative Activation of Macrophages through Interleukin-13-Loaded Extra-Large-Pore Mesoporous Silica Nanoparticles Suppresses Experimental Autoimmune Encephalomyelitis.

  2021cites this paper
• Perfil demográfico y clínico de la esclerosis múltiple en Costa Rica: revisión de la casuística nacional a diciembre de 2017

  2021cites this paper
• Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.

  2020cites this paper
• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

  2020cites this paper
• Introduction and Program Overview

  2020cites this paper
• Pharmacological management of depression in patients with multiple sclerosis

  2018cites this paper
• Interferon β for Multiple Sclerosis.

  2018cites this paper
• Producing an evidence‐based treatment information website in partnership with people affected by multiple sclerosis

  2018cites this paper
• Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis

  2017cites this paper
• Evaluating the safety of β-interferons in MS

  2017cites this paper
• Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.

  2017cites this paper
• Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis

  2017cites this paper
• Seasonal variation in multiple sclerosis relapse

  2017cites this paper
• When and how disease‐modifying drugs for multiple sclerosis should be changed in daily practice

  2017cites this paper
• Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

  2017cites this paper
• Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

  2017cites this paper
• Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar

  2017cites this paper
• Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs

  2016cites this paper
• Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait.

  2016cites this paper
• Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project

  2016cites this paper
• Multiple Sclerosis

  2016cites this paper
• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

  2016cites this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2016cites this paper
• Evaluating response to disease-modifying therapy in relapsing multiple sclerosis

  2015cites this paper
• The conundrum of interferon-β non-responsiveness in relapsing-remitting multiple sclerosis.

  2015cites this paper
• Experiences of UK health‐care services for people with Multiple Sclerosis: a systematic narrative review

  2015cites this paper
• Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS)

  2015influential citation
• Multiple sclerosis and related disorders

  2014cites this paper
• The challenges of measuring disability accumulation in relapsing–remitting multiple sclerosis: evidence from interferon beta treatments

  2014cites this paper
• Multiple sclerosis: a primary care perspective.

  2014cites this paper
• Financial Valuation Algorithm for the Assessmentof the Future Sales of a New, Innovative Medicinal Product

  2014cites this paper
• Risk evaluation and monitoring in multiple sclerosis therapeutics

  2014cites this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2014cites this paper
• Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis

  2014cites this paper
• Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

  2014cites this paper
• Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon‐β therapy

  2014cites this paper
• Disease-modifying agents in multiple sclerosis.

  2014cites this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cites this paper
• Association between beta‐interferon exposure and hospital events in multiple sclerosis

  2014cites this paper
• Fluctuations in appraisal over time in the context of stable versus non-stable health

  2014cites this paper
• Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.

  2014cites this paper
• New and emerging immune‐targeted drugs for the treatment of multiple sclerosis

  2014cites this paper
• Therapeutic Class Overview Attention Deficit/Hyperactivity Disorder (ADHD) Agents and Stimulants

  2014cites this paper
• Disease‐modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

  2014cites this paper
• Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.

  2014cites this paper
• Evidence for Long-Term Use of Intramuscular Interferon Beta-1a: An Overview of Relapse, Disability, and MRI Data from Selected Clinical Trials

  2013cites this paper
• The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.

  2013cites this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cites this paper
• Mitoxantrone for multiple sclerosis.

  2013cites this paper
• Placebo? no thanks, it might be bad for me!

  2013cites this paper
• Interferon beta and long-term disability in multiple sclerosis--reply.

  2013cites this paper
• [Disease mongering in neurological disorders].

  2013cites this paper
• Immunotherapy of Multiple Sclerosis

  2013cites this paper
• Chronische Krankheiten und der Wirt - Gesundung am Beispiel von Patienten mit Multipler Sklerose

  2013cites this paper
• Consensus guidelines for the diagnosis and treatment of multiple sclerosis

  2013cites this paper
• A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome

  2013cites this paper
• Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis

  2013cites this paper
• The American Academy of Neurology's Top Five Choosing Wisely recommendations

  2013cites this paper
• The American Academy of Neurology's Top Five Choosing Wisely recommendations

  2013cites this paper
• Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing–remitting multiple sclerosis in Sweden

  2013cites this paper
• Original article Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis inSweden

  2013cites this paper
• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

  2013cites this paper
• Interferon beta and long-term disability in multiple sclerosis.

  2013cites this paper
• The first 10 years with multiple sclerosis: the longitudinal course of daily functioning.

  2013cites this paper
• Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

  2012cites this paper
• Fingolimod: un nuevo enfoque en el tratamiento de la esclerosis múltiple

  2012cites this paper
• Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

  2012cites this paper
• Documento de consenso de LACTRIMS para el tratamiento farmacológico de la esclerosis múltiple y sus variantes clínicas

  2012cites this paper
• Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

  2012cites this paper
• Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod

  2012cites this paper
• Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.

  2012cites this paper
• A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.

  2012cites this paper
• Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

  2012cites this paper
• Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis

  2012cites this paper
• medication into perspective: review of meta-analyses Putting the efficacy of psychiatric and general medicine

  2012cites this paper
• Turning signals into meaning –‘Shared decision making’ meets communication theory

  2012cites this paper
• Interferon beta for secondary progressive multiple sclerosis.

  2012cites this paper
• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome.

  2011cites this paper
• A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

  2011cites this paper
• Überlegungen zur Wirksamkeit von Psychopharmaka

  2011cites this paper
• The Pursuit of Transparency and Quality Improvement in Cost-Effectiveness Analysis – A Case Study in Disease-Modifying Drugs for the Treatment of Multiple Sclerosis

  2011cites this paper
• Immunomodulatory medicines for multiple sclerosis: Progress and prospects

  2011cites this paper
• Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study

  2011cites this paper
• Future clinical challenges in multiple sclerosis

  2011cites this paper
• When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

  2011cites this paper
• Data mining for response shift patterns in multiple sclerosis patients using recursive partitioning tree analysis

  2011cites this paper
• Development of oral immunomodulatory agents in the management of multiple sclerosis

  2011cites this paper
• Pharmaceutical industry discursives and the marketization of nursing work: a case example.

  2011cites this paper
• Immunotherapy of multifocal motor neuropathy

  2011cites this paper
• Response shift in patients with multiple sclerosis: an application of three statistical techniques

  2011cites this paper
• Evidence Review Group's Report Template

  2011cites this paper
• Assessing changes in relapse rates in multiple sclerosis

  2010influential citation
• Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

  2010cites this paper